WHAT IS CANNABICITRAN (CBT-C or CRM)?
*There are many conflicts in reporting of cannabicitran, in regards to it’s abbreviation. Some label it CBT-C, others label it CRM. We will stick with CBT-C.
Identifying Cannabicitran (CBT-C) is one of the latest discoveries in cannabis research. Although CBT-C is very similar to some other cannabinoid compounds, researchers have yet to categorize or specifically point out what family or compound bloc CBT-C belongs to.
The cannabis plant has shown many proven benefits to humans, but there are so many more to discover and therapeutic advantages we have no inkling of.
The earliest record or mention of cannabicitran was in 2012. The compound was said to be isolated from Lebanese hashish, a Lebanese concentrate derived from cannabis.
This particular phytocannabinoid is said to be similar to a synthetic one, citrylidene-cannabis. Researchers were able to successfully isolate CBT-C even though it exists in minute quantities and sometimes isn’t even found in some cannabis plants.
The work of scientists like Robert Cahn and R. K. Razdan have been of notable importance in these discoveries.
Being a phytocannabinoid, CBT-C occurs naturally in the cannabis sativa plant. Its formulation demonstrates of a unique feature in its chemical structure. This feature is the lack of a hydrogen bond donor link.
What this means is that the compound cannot donate hydrogen atoms but rather accepts them only. With a hydrogen bond acceptor count of 2, it has a total rotatable bond count of 4.
Research has also shown that the compound has 3 undefined atom stereocenter count. Aside from its chemical properties, there are no studies to reveal other information around the formulation of the CBT-C.
The cannabis sativa plant, sometimes called marijuana, is a plant that requires more dedicated time for research to unlock its multiple features. The plant promises a future that sees the advance of research into curing ailments like cancer, schizophrenia, insomnia, and other pervasive conditions proving difficult for doctors to find a cure.
We know that CBT-C will have its functions and merits even if we can’t say them for a fact today.
HOW DOES CBT-C WORK?
There is no clinical trial to know how this compound acts with the human body receptors. There is no test to indicate if it has psychoactive tendencies. We don’t know if it acts as a receptor blockage agent.
There are a couple of reasons for this lack of professional knowledge. For one, the ongoing tussle of marijuana usage in the global sphere is a worrying risk to stakeholders. The shortage of funds and scientific capital is another explanation.
Scientists need funds to advance their cannabinoid research. However, they will not move ahead without the right legal measures and guidelines.
POSSIBLE THERAPEUTIC BENEFITS
We hope that scientists can tell us, with further research, what therapeutic advantage this compound has and whether it is psychoactive or not, and if it is an anti-agent. The lack of understanding of CBT-C functions translates to being ignorant of its therapeutic advantages.
More clinical trials, studies, and research are important. The potential of this compound is as promising as that of the hemp plant as a whole.
- Its chemical formula is C21H30O2.
- CBT-C has a molar mass of 314.5 g/mol.
- Its IUPAC name is (6AR,9R,10AS)-6,6,9-Trimethyl-3-pentyl-6A,7,8,9,10,10A-hexahydro-6H-1,9-epoxybenzo[C]chromene.
- CBT-C annotation is similar to delta8-THC, Exo-Tetrahydrocannabinol, 9-Hydroxyhexahydrocannabinol, and Hexahydrocannabinol.
PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 59444393, Cannabicitran.
Iwata N, Kitanaka S. New cannabinoid-like chromane and chromene derivatives from Rhododendron anthopogonoides. Chem Pharm Bull (Tokyo). 2011;59(11):1409-12. doi: 10.1248/cpb.59.1409. PMID: 22041081.
Cayman Chemical: https://www.caymanchem.com/product/21295/cannabicitran-(crm)